

Bioavailability and Bioequivalence Studies Experience

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Indication / Population
Alimentary tract and metabolism			
1	Drugs used in diabetes	Glimepiride	Healthy subjects
2	Lipid modifying agents	Simvastatin	Healthy subjects
3	Lipid modifying agents	Lovastatin	Healthy subjects
4	Lipid modifying agents	Rosuvastatin	Healthy subjects
5	Lipid modifying agents	Rosuvastatin	Healthy subjects
Antiinfectives for systemic use			
6	Antivirals for systemic use	Aciclovir	Healthy subjects
7	Antivirals for systemic use	Oseltamivir	Healthy subjects
8	Antibacterials for systemic use	Azithromycin	Healthy subjects
9	Antibacterials for systemic use	Azithromycin	Healthy subjects
10	Antibacterials for systemic use	Azithromycin	Healthy subjects
Antineoplastic and immunomodulating agents			
11	Antineoplastic agents	Capecitabine	Healthy subjects
12	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
13	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
14	Taxane	Paclitaxel	Metastatic breast cancer
15	Antineoplastic agents	Capecitabine	Healthy subjects
16	Antineoplastic agents	Capecitabine	Healthy subjects
17	Monoclonal antibodies	Rituximab	Non-Hodgkin Lymphoma
18	Granulocyte colony-stimulating factor	Pegfilgrastim	Neutropenia
19	Granulocyte colony-stimulating factor	Pegfilgrastim	Neutropenia
20	Antineoplastic agents	Doxorubicin Hydrochloride Liposome	Advanced Carcinoma of the Ovary
Blood and blood forming organs			
21	Antithrombotic agents	Enoxaparin sodium	Healthy subjects
Cardiovascular system			
22	Diuretics	Indapamide	Healthy subjects
23	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
24	Diuretics	Indapamide	Healthy subjects
25	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
26	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
27	Calcium channel blockers	Nitrendypine	Healthy subjects
28	Vasoprotectives	Calcium dobesilate	Healthy subjects
29	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q

Bioavailability and Bioequivalence Studies Experience

	Lp.	Therapeutic / Chemical subgroup	Chemical substance	Indication / Population	
Bioavailability and Bioequivalence Studies	30	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects	
	31	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects	
	32	Lipid modifying agents	Simvastatin	Healthy subjects	
		Dermatologicals			
	33	Monoclonal antibodies	Adalimumab	Healthy subjects	
	34	Corticosteroids	Mometasone furoate	Healthy subjects	
	35	Corticosteroids	Mometasone furoate	Healthy subjects	
	36	Flavonoid	Genistein	Healthy subjects	
	37	Corticosteroids	Mometasone furoate	Healthy subjects	
	38	Corticosteroids	Mometasone furoate	Healthy subjects	
	39	Antipsoriatics	Tacalcitol	Plaque Psoriasis	
	40	Antipsoriatics	Tacalcitol	Plaque Psoriasis	
	41	Corticosteroids	Betamethasone dipropionate	Healthy subjects	
	42	Corticosteroids	Betamethasone dipropionate and salicylic acid	Healthy subjects	
	43	Corticosteroids	Betamethasone dipropionate and salicylic acid	Healthy subjects	
	44	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects	
	45	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects	
		Genito-urinary system and sex hormones			
	46	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects	
	47	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects	
		Musculo-skeletal system			
	48	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects	
	49	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects	
	50	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects	
	51	Drugs for treatment of bone diseases	Risedronic acid	Healthy subjects	
	52	Muscle relaxants	Thiocolchicoside	Healthy subjects	
	53	Antiinflammatory and antirheumatic products	Naproxen	Healthy subjects	
	54	Drugs for treatment of bone diseases	Alendronic acid	Healthy subjects	

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q

Bioavailability and Bioequivalence Studies Experience

	Lp.	Therapeutic /Chemical subgroup	Chemical substance	Indication / Population
Bioavailability and Bioequivalence Studies	55	Anti-inflammatory and antirheumatic products	Ibuprofen	Healthy subjects
		Nervous system		
	56	Psychoanaleptics	Amitriptyline	Healthy subjects
	57	Psycholeptics	Olanzapine	Healthy subjects
	58	Antiepileptics	Topiramate	Healthy subjects
	59	Antidepressant	Memantine	Healthy subjects
	60	Psychoanaleptics	Amitriptyline	Healthy subjects
	61	Antivertigo preparations	Cinnarazinum & Dimenhydrinatum	Healthy subjects
	62	Psychoanaleptics	Mirtazapine	Healthy subjects
	63	Other nervous system drugs	Betahistine	Healthy subjects
	64	Antiepileptics	Topiramate	Healthy subjects
	65	Antiepileptics	Lamotrigine	Healthy subjects
	66	Antiepileptics	Pregabalin	Healthy subjects
	67	Psychoanaleptics	Aniracetam	Healthy subjects
	68	Anti-parkinson drugs	Rasagiline	Healthy subjects
		Respiratory system		
	69	Antihistamines	Clemastine	Healthy subjects
	70	Antihistamines	Levocetirizine	Healthy subjects
	71	Nasal preparations	Fluticasone furoate	Healthy subjects
	72	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
	73	Antihistamines	Loratadine	Healthy subjects
	74	Antihistamines	Levocetirizine	Healthy subjects
	75	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
		Various		
	76	Antiinflammatory / Sympathomimetics	Ibuprofen / Pseudoephedrine	Healthy subjects

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q